In vitro susceptibility of dermatophytes to conventional and alternative antifungal agents

References

• Das S, Goyal R, Bhattacharya SN. Laboratory-based epidemiological study of superficial fungal infections. J Dermatol 2007; 34: 248–253
   PubMedGoogle Scholar
• Ginter-Hanselmayer G, Weger W, Ilkit M, et al. Epidemiology of tinea capitis in Europe: current state and changing patterns. Mycoses 2007; 50: 6–13
   PubMed Web of Science ®Google Scholar
• Hernández-Salazar A, Carbajal-Pruneda P, Fernández Martínez R, et al. Dermatophytosis due to Trichophyton rubrum. Ten-year period (1996–2006) data collection in a Dermatology Department in Mexico City. Rev Iberoam Micol 2007; 24: 122–124
   PubMedGoogle Scholar
• Porro AM, Yosioka CN, Kaminski SK, et al. Disseminated dermatophytoses caused by Microsporum gypseum in two patients with the Acquired Immunodeficiency Virus. Mycopathologia 1997; 137: 9–12
   PubMed Web of Science ®Google Scholar
• Seyfarth F, Ziemer M, Gräser Y, et al. Widespread tinea corporis caused by Trichophyton rubrum with non-typical cultural characteristics-diagnosis via PCR. Mycoses 2007; 50: 26–30
   Google Scholar
• Barchiesi F, Arzeni D, Camilletti V, et al. In vitro activity of posaconazole against clinical isolated of dermatophytes. J Clin Microbiol 2001; 39: 4208–4209
   PubMed Web of Science ®Google Scholar
• Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet 2001; 40: 441–472
   PubMed Web of Science ®Google Scholar
• Fernandez-Torres B, Inza I, Guarro J. Comparison of in vitro antifungal susceptibilities of conidia and hyphae of dermatophytes with thick-wall macroconidia. Antimicrob Agents Chemother 2003; 47: 3371–3372
   Google Scholar
• Fernandez-Torres B, Cabañes FJ, Carrillo-Muñoz AJ, et al. Collaborative study of optimal antifungal susceptibility testing conditions for dermatophytes. J Clin Microbiol 2002; 40: 3999–4003
   PubMed Web of Science ®Google Scholar
• Fernandez-Torres B, Carrillo AJ, Martin E, et al. In vitro activities of 10 antifungal drugs against 508 dermatophytes strains. Antimicrob Agents Chemother 2001; 45: 2524–2528
   PubMed Web of Science ®Google Scholar
• Fernandez-Torres B, Vazquez-Veiga H, Liovo X, et al. In vitro susceptibility to itraconazole, clotrimazole, ketoconazole and terbinafine of 100 isolates of Trichophyton rubrum. Chemotherapy 2000; 46: 390–394
   PubMed Web of Science ®Google Scholar
• Millikan LE. Role of oral antifungal agents for the treatment of superficial fungal infections in immunocompromised patients. Cutis 2001; 68: 6–14
   Google Scholar
• Niewerth M, Korting HC. The use of systemic antimycotics in dermatotherapy. Eur J Dermatol 2000; 10: 155–160
   PubMed Web of Science ®Google Scholar
• Boudghere-Stambouli O, Merad-Boudia A. Antifungal agents in dermatophytic disease: failure of griseofulvin, ketoconazole and itraconazole drug resistance dermatomycoses. Bull Soc Pathol Exot 1990; 83: 170–176
   Google Scholar
• Aliò AB, Mendoza M, Zambiano EA, et al. Dermatophytes growth curve and in vitro susceptibility test: a broth micro-titration method. Med Mycol 2005; 43: 319–325
   Google Scholar
• Boman HG. Antibacterial peptides: key components needed in immunity. Cell 1991; 65: 205–207
   PubMed Web of Science ®Google Scholar
• Hancock R, Chapple DS. Peptides antibiotics. Antimicrob Agent Chemother 1999; 43: 1317–1323
   PubMed Web of Science ®Google Scholar
• Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin Microbiol Rev 2006; 19: 491–511
   PubMed Web of Science ®Google Scholar
• Sevcsik E, Pabst G, Jilek A, et al. How lipids influence the mode of action of membrane-active peptides. Biochim Biophys Acta 2007; 1768: 2586–2595
   Google Scholar
• Shai Y. Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. Biochim Biophys Acta 1999; 1462: 55–70
   PubMed Web of Science ®Google Scholar
• Carson CF, Hammer KA, Riley TV. Melaleuca alternifolia (Tea Tree) oil: a review of antimicrobial and other medicinal properties. Clin Microbiol Rev 2006; 19: 50–62
   PubMed Web of Science ®Google Scholar
• Kamysz W, Kochanska B, Kędzia A, et al. Sthaterin SV2 and its analogue. Synthesis and evaluation of antimicrobial activity. Pol J Chem 2002; 76: 801–806
   Google Scholar
• National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi; proposed standard. NCCLS document M38-P. 1998 National Committee for Clinical Laboratory Standards, Wayne, PA.
   Google Scholar
• Santos DA, Barros MES, Hadan JS. Establishing a method of inoculum preparation for susceptibility testing of Trichophyton rubrum and Trichophyton mentagrophytes. J Clin Microbiol 2006; 44: 98–101
   PubMedGoogle Scholar
• Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 2004; 17: 268–280
   PubMed Web of Science ®Google Scholar
• Bernhard J, Martin E, Stueben A, et al. Susceptibility testing of Candida albicans and Aspergillus species by a sinple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazol)-2,5-diphenyl-2H-tetrazolium bromide assay. J Clin Microbiol 1995; 33: 661–667
   Google Scholar
• Barchiesi F, Giacometti A, Cirioni O, et al. In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH2 alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans. Peptides 2007; 28: 1509–1513
   Google Scholar